Skip to content

Next-Generation Sequencing (NGS) for the Study of the Mechanism of Crizotinib Resistance in Patients with ROS1 Positive Non-Small Cell Lung Cancer (NSCLC).

Next-Generation Sequencing (NGS) for the Study of the Mechanism of Crizotinib Resistance in Patients with ROS1 Positive Non-Small Cell Lung Cancer (NSCLC).

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034441
Enrollment
Unknown
Registered
2020-07-05
Start date
2020-07-06
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

case series:Nil

Sponsors

National Cancer Center / cancer hospital, Peking Union Medical College, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with advanced primary non-small cell lung cancer diagnosed by pathology or cytology; 2. In patients without dysfunction of main organs, blood routine, lung, liver, kidney and heart functions were basically normal; 3. Ros1 fusion was detected by fish, PCR or NGS; 4. Patients who agreed to receive oral targeted therapy with clotriminib; 5. Patients who understand the risk of treatment and sign informed consent voluntarily.

Exclusion criteria

Exclusion criteria: 1. Patients with disorder of thinking or consciousness, poor compliance and no complete behavior ability; 2. Patients with malignant tumor in cancer family or known family; 3. Patients who had previously suffered from other malignant tumors except lung cancer.

Design outcomes

Primary

MeasureTime frame
Crizotinib resistance;

Countries

China

Contacts

Public ContactXingsheng Hu

National Cancer Center / Cancer Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences

huxingsheng66@163.com+86 13641361385

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026